泽泻汤对代谢综合征大鼠治疗作用及机理的探讨
摘要
目的:探讨泽泻汤对代谢综合征(MS)大鼠的治疗作用及其分子机理。方法:以高糖高脂饲料建立MS大鼠(雌雄)模型,将模型大鼠分为3组,分别给予泽泻汤(中药组)、西布曲明(西药组)和生理盐水(盐水组)灌胃,并继续高糖高脂饮食,连续4周。观察大鼠体重相关指标、血糖、血脂、血清胰岛素、瘦素和血浆神经肽Y(NPY)含量。应用免疫组化法检测下丘脑Ghrelin、TNF-α,NPY及其Y1受体亚型(NPYY1R,Y1R)和胰岛NPY及Y1R,用image-pro plus6.0进行平均光密度分析。结果:中药组大鼠体重、血糖、血脂(TG、TC、LDL-c)、血清胰岛素和瘦素、血浆NPY含量均显著降低;下丘脑Ghrelin、NPY及Y1R和胰岛NPY及Y1R平均光密度值亦显著低于生理盐水对照组。结论:泽泻汤能抑制MS大鼠的体重增长,降低血糖,调节脂代谢,其作用可能通过抑制下丘脑Ghrelin合成,下调下丘脑和胰岛NPY及Y1R的表达,从而调节摄食中枢兴奋性,改善胰岛B细胞功能,纠正胰岛素抵抗和瘦素抵抗而实现的。
Objective To explore the therapeutic effects of Zexie Tang on Metabolic syndrome(MS) rats as well as to make a study on the molecular mechanism. Methods Rats models(males and females) of Metabolic Syndrome were established by high sugar & fat diet, then they were randomly divided into 3 groups, including ZeXieTang decoction(TCM group), sibutramine (western medicine group) and saline group. After 4 weeks of oral administration and high sugar & fat diet, the changes of body weight and associated indicators, the levels of fasting blood-glucose(FBG), lipids, fasting insulin, serum leptin and plasma NPY were examined respectively. Meanwhile, Ghrelin, TNF-α, NPY and Y1 receptor subtype (NPYY1R,Y1R) in hypothalamus, NPY and Y1R in pancreatic islets were tested by immunohistochemistry. The density mean was analyzed by image-pro plus6.0. Results The body weight, levels of FBG, lipids, insulin, leptin and plasma NPY were reduced significantly in TCM group. The density mean of Ghrelin, NPY and Y1R in hypothalamus and of NPY and Y1R in pancreatic islets were significantly lower in TCM group than those in saline group. Conclusion Zexie Tang can inhibit the growth of body weight of MS rats, reduce the level of FBG and regulate lipid metabolism probably by inhibiting the synthesis of NPY and the expression of Y1R in hypothalamus and pancreatic islets, by which restrained the synthesis of Ghrelin in hypothalamus, regulated the excitability of the feeding center, improved the functions of pancreatic islets B cells and reduced the insulin resistance and leptin resistance.
Objective To explore the therapeutic effects of Zexie Tang on Metabolic syndrome(MS) rats as well as to make a study on the molecular mechanism. Methods Rats models(males and females) of Metabolic Syndrome were established by high sugar & fat diet, then they were randomly divided into 3 groups, including ZeXieTang decoction(TCM group), sibutramine (western medicine group) and saline group. After 4 weeks of oral administration and high sugar & fat diet, the changes of body weight and associated indicators, the levels of fasting blood-glucose(FBG), lipids, fasting insulin, serum leptin and plasma NPY were examined respectively. Meanwhile, Ghrelin, TNF-α, NPY and Y1 receptor subtype (NPYY1R,Y1R) in hypothalamus, NPY and Y1R in pancreatic islets were tested by immunohistochemistry. The density mean was analyzed by image-pro plus6.0. Results The body weight, levels of FBG, lipids, insulin, leptin and plasma NPY were reduced significantly in TCM group. The density mean of Ghrelin, NPY and Y1R in hypothalamus and of NPY and Y1R in pancreatic islets were significantly lower in TCM group than those in saline group. Conclusion Zexie Tang can inhibit the growth of body weight of MS rats, reduce the level of FBG and regulate lipid metabolism probably by inhibiting the synthesis of NPY and the expression of Y1R in hypothalamus and pancreatic islets, by which restrained the synthesis of Ghrelin in hypothalamus, regulated the excitability of the feeding center, improved the functions of pancreatic islets B cells and reduced the insulin resistance and leptin resistance.
引文
[1] Eckel RH,Grundy SM,Zimmet PZ.The metabolic syndrome.Lancet,2005;365(9468):1415—1428.
[2] Reaven GM.Banting lecture 1988 . Role of insulin resistance in human disease.Diabetes,1988;37(12):1595-1607.
[3] Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition.Lancet,2005;366(9491):1059-1062.
[4]顾东风,REYNOLDS K,杨文杰,等.中国成年人代谢综合征的患病率.中华糖尿病杂志,2005;13(3):181-186.
[5]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议.中华糖尿病杂志,2004;12(3):156-161.
[6] Zhang Y, Proenca R, Maffei M,et al.Positional cloning of the mouse obese gene and its human homologue.Nature,1994;372(6505):425-432.
[7] Clement K, Garner C, Hager J,et al. Indication for linkage of the human OB gene region with extreme obesity.Diabetes,1996;45(5) :687-690.
[8]张继峰.肥胖基因的研究进展.生理科学进展,1998;29(1):24-28.
[9] Banks WA,Kastin AJ,Huang W,et al.Leptin enters the brain by a saturable system independent of insulin.Peptides,1996;17(2):305-3l1.
[10] Tena—Sempere M,Pinilla L,Gonzalez LC,et al.In Vitro pituitary and testicular effects of leptin-related synthetic peptide leptin (116-130)amide involve actions both similar to and distinct from those of the native leptin molecule in the adult rat。Eur J Endocrino1,2000;142(4):406-410
[11]王薇,李强,张巾超.瘦素的生物学特性研究现状.哈尔滨医科大学学报,2002;36(4):337-338.
[12]李强.瘦素、瘦素受体及其信号转导.第二军医大学学报,2007;28(7) :752-755.
[13] Ghilardi N,Skoda RC.The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line.Mol Endocrino1,1997;11(4):393-399.
[14] Ellacott KL,Cone RD. The central melanocortin system and the integration ofshort-and long-term regulators of energy homeostasis.Recent Prog Horm Res,2004,59(2):395-408.
[15]邹增丁,陈立祥.瘦素的生物学功能及其对脂肪代谢调控的研究进展.饲料博览,2007;13(7) :12-15.
[16] Misra A, Arora N , Mondal S,et al . Relation between plasma leptin and anthropometric and metabolic covariates in lean and obese diabetic and hyperlipidaemic Asian Northern Indian subjects.Diabetes Nutr Metab,2001;14(1):18-26.
[17] Ostlund RE Jr,Yang JW,Klein S,et al.Relation between plasma leptin concentration and body fat,gender,diet,age,and metabolic covariates.J Clin Endocrinol Metab,1996;81(11):3909-3913.
[18] Tatemoto K, Carlquist M,Mutt V.Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.Nature,1982;296(5858):659-660.
[19]范艳萍,石建华,项平.神经肽Y结构和作用.实用全科医学,2007;5(6) :537-538.
[20] Marklund U,Bystrom M,Gedda K,et al.Intron—mediated expression of the human neuropeptide Y Y1 receptor.Mol Cell Endocrinol,2002;188(1-2):85-97.
[21] Ishihara A,Kanatani A,Mashiko S,et al.A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.PNAS,2006;103(18):7154-7158.
[22] Pittner RA,Moore CX,Bhavsar SP,et al.Effects of PYY[3-36]in rodent models of diabetes and obesity.Obes Relat Metab Disord,2004;28(8):963-971.
[23] Cho YR,Kim CW.Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun,2004;314(3) : 773-780.
[24] Inui A.Neuropeptide Y feeding receptors:are mu1tiple subtypes involved?.Trends in Pharmacological Sciences,1999;20(2):43-46.
[25] Kalra PS,Kalra SP. Use of antisense oligodeoxynucleotides to study the physiological functions of neuropeptide Y.Methods,2000;22(3):249-254.
[26] Billington CJ, Briggs JE,Harker S,et al.Neuropeptide Y in hypothalamicparaventricular nucleus:a center coordinating energy metabolism.AM J physiol,1994;266(6 Pt 2):1765-1770.
[27] Dryden S,Frankish H,Wang Q,et al.Neuropeptide Y and energy balance:one way ahead for the treatment of obesity?.Eur J Clin Invest,1994;24(5):293-308.
[28] Marks AR.Calcium channels expressed in vascular smooth muscle.Circulation,1992;86(6 Suppl):11161-11167.
[29] Sun X,Edvinsson L,Hedner T.Cardiovascular effects of alpha-trinositol in spontaneously hypertensive and normotensive Wistar-Kyoto rats.J Hypertens,1993;11(9):935-943.
[30] Fior-Chadi DR,Fuxe K.Quantitative receptor radioautography in the study of receptor-receptor interactions in the nucleus tractus solitarii.Braz J Med Biol Res,1998;31(2):225-230.
[31]陈敏生,刘健康,黄步华.神经肽Y对培养的血管平滑肌细胞增殖的影响.中山医科大学学报,1999;20(3):207-209.
[32] Neild TO,Lewis CJ.Reduction of vasoconstriction mediated by neuropeptide Y Y2 receptors in arterioles of the guinea-pig small intestine.Br J pharmcol,1995;115(2):220-221.
[33] Kojima M,Hosoda H,Date Y,et al. Ghrelin is a growth—hormone—releasing acylated peptide from stomach.Nature,l999;402(6762):656—660.
[34] Hosoda H,Kojima M,Matsuo H,et al.Ghrelin and des-acyl ghrelin:two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun,2000;279(3):909—913.
[35] Howard A D,Feighner SD,Cully D F,et al.A Receptor in Pituitary and Hypothalamus that Function in Growth Hormone Release.Science,1996,273(5277):974-977.
[36] Kohno D , Gao HZ , Muroya S , et al . Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes,2003;52(4):948-956.
[37] Kamegai J,Tamura H,Shimizu T,et al.Chronic central infusion of ghrelin increaseshypothalamic neuropeptide Y and Agouti-Related protein mRNA levels and body weight in rats.Diabetes,2001;50(11):2438-2443.
[38] Nieminen P, Mustonen AM.Effects of peripheral ghrelin on the carbohydrate and lipid metabolism of the tundra vole (Microtus oeconomus). Gen Comp Endocrinol,2004;138(2) :182-187.
[39]祝之明.代谢综合征病因探索与临床实践,北京:人民军医出版社,2005,1:136.
[40] Saad MF,Bernaba B,Hwu CM, et al. Insulin regulates plasma ghrelin concentration.J Clin Endocrinol Metab,2002;87(8) :3997-4000.
[41] McLaughlin T,Abbasi F,Lamendola C, et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab,2004;89(4) :1630-1635.
[42] Erdmann J , Lippl F , Wagenpfeil S , et al . Differential association of basal and postprandial plasma ghrelin with leptin , insulin , and type 2 diabetes. Diabetes,2005;54(5) :1371-1378.
[43] Soriano-Guillen L,Barrios V,Lechuga-Sancho A,et al.Response of circulating ghrelin levels to insulin therapy in children with newly diagnosed type 1 diabetes mellitus.Pediatric Res,2004;55(5):830-835.
[44] Reimer MK,Pacini G,Ahren B. Dose-Dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology,2003,144(3):916-921.
[45] Carswell EA,Old LJ,Kassel RL,et al.An endotoxin—induced serum factor that cause necrosis of tumors.Proc.nat1.Acad.Sci.USA,1975,72(9):3666-3670.
[46] Lofgren P,Van Harmelen V,Reynisdottir S,et al. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue.Diabetes,2000;49(5):688-692.
[47] Nicaud V,Raoux S, Poirier O,et al.The TNF alpha/G308A polymorphism influences insulin sensitivity in offspring of patients with coronary heart disease: the European Atherosclerosis Research StudyⅡ. Atherosclerosis,2002;161(2):317-325.
[48]孟德连,林亚秋,杨公社,等.肿瘤坏死因子-α(TNF-α)与肥胖.黄牛杂志,2004;30(2):32-35.
[49] Declercq W, Vandenabeele P,Fiers W. Dimerization of chimeric erythropoietin/75kDa tumour necrosis factor (TNF) receptors transduces TNF signals:necessity for the 75 kDa-TNF receptor transmembrane domain.Cytokine,1995;7(7):701-709.
[50] Herrmann SM, Ricard S, Nicaud V, et al.Polymorphisms of the tumour necrosis factor—alpha gene,coronary heart disease and obesity.Eur J Clin Invest,1998;28(1):59-66.
[51] Katsuki A,Sumida Y, Murashima S,et al.Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab,1998;83(3):859-862.
[52] Rosmand R. Associntion studies of genetic polymorphisms in central obesity:a critical review. International Journal of Obesity,2003(27) :1141-1151.
[53] Prins JB,Niesler CU,Winterford CM,et al.Tumor necrosis factor-alpha induces apoptosis of human adipose cell. Diabetes,1997;46(12):1939—1944.
[54] Nisoli E,Carruba MO,Tonello C,et al.Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2,leptin,uncoupling proteins 2 and 3 ,and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes,2000;49(3):319—324.
[55] Doerrler W,Feingold KR,Grunfeld C.Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms.Cytokine,1994;6(5):478-484.
[56]邓正照,钱荣立.糖尿病脂代谢异常与治疗.中国糖尿病杂志,2001,9(4):251-254.
[57] Engelman JA, Berg AH,Lewis RY,et al.Tumor necrosis factor alpha-mediated insulin resistance,but not dedifferentiation,is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes.Mol Endocrinol,2000;14(10):1557-1569.
[58]王琦.9种基本中医体质类型的分类及其诊断表述依据.北京中医药大学学报,2005;28(4):1-8.
[59]董静,王琦,王东坡,等.从痰湿体质角度论析代谢综合征.北京中医药大学学报,2006;29(12):802-803.
[60]谢淑芸,霍艳明.试述代谢综合征的病因病机.中华实用中西医杂志,2007;20(13):1186-1187.
[61]卢立广,叶子.滋阴清心汤治疗代谢综合征63例观察.浙江中医杂志,2005;40(5):200.
[62]朗宁,刘贵阳.代谢综合征证治探讨.中医药学刊,2005;23(1):1289-1290.
[63]徐远.中医治疗代谢综合征的思路与方法.中医杂志,2003;44(4):301-302.
[64]刘志龙,李锡杰.浅谈代谢综合征的辨证论治.新中医,2007;39(3):88-89.
[65]王德玉.论肝与代谢综合征.浙江中西医结合杂志,2004;14(1):23-24.
[66]刘荣东,黄如萍.痰证与代谢综合征关系的探讨.中国中医基础医学杂志,2006;12(12):947-948.
[67]李东晓.痰与代谢综合征.中国中医基础医学杂志,2005;11(2):144-146.
[68]王群江,潘智敏.痰瘀因素与代谢综合征.辽宁中医药大学学报,2006;8(6):76.
[69]张雪红,宋巧凤.桃红四物汤加减治疗X综合征20例.中国中医急症,2002;11(2):137.
[70]潘善余.代谢综合征的病因病机及治疗.中医药学刊,2006;24(10):1805-1806.
[71]魏治鹏,郭宏敏.代谢综合征中的郁和瘀.辽宁中医杂志,2006;33(7):803-804
[72]李晓政,闫彩香.益肾法治疗代谢综合征痰瘀证.中国中医药信息杂志,2007;14(2):19-21.
[73]仝小林,张志远.中医对代谢综合征的认识和治疗.中医杂志,2OO2;43(9):708-709.
[74]王琦,李英帅.中医对代谢综合征的认识及辩治探讨(下).浙江中医杂志,2006;41(11):623-625.
[75]张兴军.黄连温胆汤加味治疗代谢综合征(MS)18例.中国当代医学,2006;20(5):93.
[76]陈义春,吴隆庆.益气降浊祛瘀方干预治疗代谢综合征临床观察.中国中医药信息杂志,2007;14(1):75.
[77]欧阳钢,舒琳,徐小梅,等.针刺干预治疗代谢综合征的临床研究.中国针灸学会临床分会第十五届全国针灸学术研讨会论文集,2007:78-82.
[78]翟耀,巩殿琴,陈德成,等.针刺治疗糖尿病及心血管并发症的临床研究.中国针灸,1996;8:11-13.
[79]李春娟,徐太生,冯占荣.仲景五苓散法对实验性代谢综合征大鼠高血压的影响.吉林中医药,2007;27(5):56.
[80]赵瑛,李蔚,祖莹,等.葛根素对实验性代谢综合征大鼠血脂影响的研究.中国中医药科技,2007;14(1):29-30.
[81]顾国龙,刘铮.泽泻汤治疗高血压病合并高脂血症.湖北中医杂志,2003;25(4):9-10.
[82]姜剑华,姜华新.泽泻汤加味治疗梅尼埃病68例.中华中西医学杂志,2005;3(6) :93-94.
[83]王玉仙,马学荣.泽泻汤加味治疗高脂血症103例.陕西中医,2005;26(2) :103-104.
[84]陈利群.半夏白术天麻汤合泽泻汤加味对痰湿壅盛型高血压病体重指数、降压效果的影响.中国中医急症,2007;16(6) :650-651.
[85]方校良,竹剑平.大黄壳聚糖片的减肥药效研究.浙江中西医结合杂志,2000;10(12):724-725.
[86]李媛,王保芝,岂春晓,等.一种新的肥胖大鼠模型的制备方法.河北医科大学学报,2005;26(4):305-307.
[87] Dobiasova M,Frohlich J.The plasma parameter log(TG/HDL-c)as an atherogenic index:correlation with lipoprotein particle size and esterification rate in apoB—lipoprotein—depleted plasma(FER(HDL)).Clin Bioc,2001;34(7):583-588.
[88]李光伟,潘孝仁,lilliojas,等.检测人群胰岛素敏感性的一项新指数.中华内科学杂志,1993;32(10):656-660.
[89]郭宏昌,牛晓亚,张向东,等.痰浊证与血脂水平关系的研究.河南中医药学刊,1998;13(6):18.
[90]周美芳.从痰瘀论治高脂血症88例临床观察.贵阳中医学院学报,2005;27(1):43.
[91]张永涛.论酶与NIDDM胰岛素抵抗的关系.河南中医,2001;21(6):3-5.
[92]职利琴,裴纪文,周数之.痰瘀与原发性高血压病.陕西中医,2002;23(2):140-141.
[93]张丽霞,宰军华,张钦现.二陈汤合泽泻汤对实验性高脂血症大鼠血脂的调节作用.中国实验方剂学杂志,1998;6(4):61.
[94]李晨辉,尉中民,张秋菊,等.泽泻汤加味防治高脂血症及利胆作用的实验研究.北京中医,2001;(6):46-48.
[95]唐雪梅,翟玉祥,刘涛,等.加味泽泻饮对实验性高脂血症大鼠血液流变学及血清一氧化氮的影响.中国实验方剂学杂志,2006;12(5):26-28.
[96] Aiston S,Agius L. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin.Diabetes,1999;48(1):15-20.
[97] Shek EW,Brands MW,Hall JE.Chronic leptin infusion increase arterial pressure. Hypertension,1998;31(1 Pt 2):409-414.
[98] Chua SC Jr,Chung WK, Wu-Peng XS,et al.Phenotypes of mouse diabetes and rat fatty due to mutations in the OB(1eptin)receptor.Science,1996;271(5251):994-996.
[99] Dieguez C,Casanueza FF.Ghrelin:a step forward in the understanding of somatotroph cell function and growth regulation.Eur J Endocrinol,2000;142(5):413-417.
[100] Liu X, York DA , Bray GA. Regulation of ghrelin gene expression in stomach and feeding response to a ghrelin analogue in two strains of rats. Peptides,2004;25 (12):2171-2177.
[101] Nakazato M,Murakami N ,Date Y,et al.A role for ghrelin in the central regulation of feeding.Nature,2001;409(6817):194-l98.
[102] Shintani M,Ogawa Y,Ebihara K,et al.Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes,200l;50(2):227-232.
[103]李琳,吴永华,洪天配,等.Ghrelin抑制胰岛β细胞胰岛素释放的机制探讨.中国糖尿病杂志.2006;14(6):452—454.
[104]毛微波,郭晓蕙,高妍,等.Ghrelin促进大鼠胰岛素合成及高葡萄糖诱导的胰岛素分泌.基础医学与临床,2004,24(4) :432-435.
[105] Hotamisligil GS,Shargill NS,Spiegelman BM.Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance.Science,1993;259(5091):87-91.
[106] Hotamisligil GS,Spiegelman BM.Tumor necrosis factor-alpha:a key component of the obesity-diabetes link.Diabetes,1994;43 (11):1271—1278.
[107] Uysal KT,Wiesbrock SM,Marino MW,et al.Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function.Nature,1997;389 (6651):610—614.
[108] Uysal KT,Wiesbrock SM,Hotamisligil GS.Functional analysis of tumor necrosis factor(TNF)receptors in TNF-alpha-mediated insulin resistance in genetic obesity.Endocrinology,1998;139 (12):4832—4838.
[109] Borst SE, Lee y, Conover CF, et al.Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle,but not adipose tissue.Am J Physiol Endocrinol Metab,2004;287(5):934-938.
[110] Moller DE.Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.Trends Endocrinol Metab,2000;11(6):212—217.
[111] Tagami S, Inokuchi Ji J, Kabayama K, et al.Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem,2002;277(5) :3085-3092.
[112] Lofgren P, van Harmelen V ,Reynisdottir S,et al.Secretion of tumor necrosid factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue.Diabetes,2000;49(5):688-692.
[113]邹大进.蛋白酪氨酸磷酸酶1B的普遍激活:胰岛素抵抗和瘦素抵抗可能的共同发病机制.国际内分泌代谢杂志,2007;27(5) :293-295.
[114]王重建,杨年红,许明佳,等.肥胖和肥胖抵抗大鼠神经肽Y及其受体基因表达的研究.营养学报,2006;28(2) :116-119.
[115] Milewicz A,Mikulski E,Bidzinska B. Plasma insulin, cholecystokinin,galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus. Int J Obes Relat Metab Disord,2000;24 suool 2:152-153.
[116] Myrsen-Axcrona U,Karlsson S,Sundler F , et al. Dexamethasone induces neuropeptide Y(NPY) expression and impairs insulin release in the insulin- producing cell line RINm5F.Release of NPY and insulin through different pathways. Journ Biol Chem,1997;272(16):1079O-10796.
[117] Wang ZL,Bennet WM,Wang RM,et al. Evidence of a paracrine role of neuronpeptide-Y in the regulation of insulin release from pancreaticislets of normal and dexamethasone-treated rats. Endocrinology,1994;135(1):200-206.
[118]梁凤霞,陈瑞,王华,等.针刺对糖尿病大鼠血浆神经肽Y的影响.中国针灸,2004;24(12):860-862.
[119] Adeghate E,Ponery AS,Pallot DJ,et al. Distribution of vasoactive intestinal polypeptide,neuropeptide-Y and substance P and their effects on insulin secretion from the in vitro pancreas of normal and diabetic rats.PePtides,2001;22(1):99-107.
[2] Reaven GM.Banting lecture 1988 . Role of insulin resistance in human disease.Diabetes,1988;37(12):1595-1607.
[3] Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition.Lancet,2005;366(9491):1059-1062.
[4]顾东风,REYNOLDS K,杨文杰,等.中国成年人代谢综合征的患病率.中华糖尿病杂志,2005;13(3):181-186.
[5]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议.中华糖尿病杂志,2004;12(3):156-161.
[6] Zhang Y, Proenca R, Maffei M,et al.Positional cloning of the mouse obese gene and its human homologue.Nature,1994;372(6505):425-432.
[7] Clement K, Garner C, Hager J,et al. Indication for linkage of the human OB gene region with extreme obesity.Diabetes,1996;45(5) :687-690.
[8]张继峰.肥胖基因的研究进展.生理科学进展,1998;29(1):24-28.
[9] Banks WA,Kastin AJ,Huang W,et al.Leptin enters the brain by a saturable system independent of insulin.Peptides,1996;17(2):305-3l1.
[10] Tena—Sempere M,Pinilla L,Gonzalez LC,et al.In Vitro pituitary and testicular effects of leptin-related synthetic peptide leptin (116-130)amide involve actions both similar to and distinct from those of the native leptin molecule in the adult rat。Eur J Endocrino1,2000;142(4):406-410
[11]王薇,李强,张巾超.瘦素的生物学特性研究现状.哈尔滨医科大学学报,2002;36(4):337-338.
[12]李强.瘦素、瘦素受体及其信号转导.第二军医大学学报,2007;28(7) :752-755.
[13] Ghilardi N,Skoda RC.The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line.Mol Endocrino1,1997;11(4):393-399.
[14] Ellacott KL,Cone RD. The central melanocortin system and the integration ofshort-and long-term regulators of energy homeostasis.Recent Prog Horm Res,2004,59(2):395-408.
[15]邹增丁,陈立祥.瘦素的生物学功能及其对脂肪代谢调控的研究进展.饲料博览,2007;13(7) :12-15.
[16] Misra A, Arora N , Mondal S,et al . Relation between plasma leptin and anthropometric and metabolic covariates in lean and obese diabetic and hyperlipidaemic Asian Northern Indian subjects.Diabetes Nutr Metab,2001;14(1):18-26.
[17] Ostlund RE Jr,Yang JW,Klein S,et al.Relation between plasma leptin concentration and body fat,gender,diet,age,and metabolic covariates.J Clin Endocrinol Metab,1996;81(11):3909-3913.
[18] Tatemoto K, Carlquist M,Mutt V.Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.Nature,1982;296(5858):659-660.
[19]范艳萍,石建华,项平.神经肽Y结构和作用.实用全科医学,2007;5(6) :537-538.
[20] Marklund U,Bystrom M,Gedda K,et al.Intron—mediated expression of the human neuropeptide Y Y1 receptor.Mol Cell Endocrinol,2002;188(1-2):85-97.
[21] Ishihara A,Kanatani A,Mashiko S,et al.A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.PNAS,2006;103(18):7154-7158.
[22] Pittner RA,Moore CX,Bhavsar SP,et al.Effects of PYY[3-36]in rodent models of diabetes and obesity.Obes Relat Metab Disord,2004;28(8):963-971.
[23] Cho YR,Kim CW.Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun,2004;314(3) : 773-780.
[24] Inui A.Neuropeptide Y feeding receptors:are mu1tiple subtypes involved?.Trends in Pharmacological Sciences,1999;20(2):43-46.
[25] Kalra PS,Kalra SP. Use of antisense oligodeoxynucleotides to study the physiological functions of neuropeptide Y.Methods,2000;22(3):249-254.
[26] Billington CJ, Briggs JE,Harker S,et al.Neuropeptide Y in hypothalamicparaventricular nucleus:a center coordinating energy metabolism.AM J physiol,1994;266(6 Pt 2):1765-1770.
[27] Dryden S,Frankish H,Wang Q,et al.Neuropeptide Y and energy balance:one way ahead for the treatment of obesity?.Eur J Clin Invest,1994;24(5):293-308.
[28] Marks AR.Calcium channels expressed in vascular smooth muscle.Circulation,1992;86(6 Suppl):11161-11167.
[29] Sun X,Edvinsson L,Hedner T.Cardiovascular effects of alpha-trinositol in spontaneously hypertensive and normotensive Wistar-Kyoto rats.J Hypertens,1993;11(9):935-943.
[30] Fior-Chadi DR,Fuxe K.Quantitative receptor radioautography in the study of receptor-receptor interactions in the nucleus tractus solitarii.Braz J Med Biol Res,1998;31(2):225-230.
[31]陈敏生,刘健康,黄步华.神经肽Y对培养的血管平滑肌细胞增殖的影响.中山医科大学学报,1999;20(3):207-209.
[32] Neild TO,Lewis CJ.Reduction of vasoconstriction mediated by neuropeptide Y Y2 receptors in arterioles of the guinea-pig small intestine.Br J pharmcol,1995;115(2):220-221.
[33] Kojima M,Hosoda H,Date Y,et al. Ghrelin is a growth—hormone—releasing acylated peptide from stomach.Nature,l999;402(6762):656—660.
[34] Hosoda H,Kojima M,Matsuo H,et al.Ghrelin and des-acyl ghrelin:two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun,2000;279(3):909—913.
[35] Howard A D,Feighner SD,Cully D F,et al.A Receptor in Pituitary and Hypothalamus that Function in Growth Hormone Release.Science,1996,273(5277):974-977.
[36] Kohno D , Gao HZ , Muroya S , et al . Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes,2003;52(4):948-956.
[37] Kamegai J,Tamura H,Shimizu T,et al.Chronic central infusion of ghrelin increaseshypothalamic neuropeptide Y and Agouti-Related protein mRNA levels and body weight in rats.Diabetes,2001;50(11):2438-2443.
[38] Nieminen P, Mustonen AM.Effects of peripheral ghrelin on the carbohydrate and lipid metabolism of the tundra vole (Microtus oeconomus). Gen Comp Endocrinol,2004;138(2) :182-187.
[39]祝之明.代谢综合征病因探索与临床实践,北京:人民军医出版社,2005,1:136.
[40] Saad MF,Bernaba B,Hwu CM, et al. Insulin regulates plasma ghrelin concentration.J Clin Endocrinol Metab,2002;87(8) :3997-4000.
[41] McLaughlin T,Abbasi F,Lamendola C, et al. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab,2004;89(4) :1630-1635.
[42] Erdmann J , Lippl F , Wagenpfeil S , et al . Differential association of basal and postprandial plasma ghrelin with leptin , insulin , and type 2 diabetes. Diabetes,2005;54(5) :1371-1378.
[43] Soriano-Guillen L,Barrios V,Lechuga-Sancho A,et al.Response of circulating ghrelin levels to insulin therapy in children with newly diagnosed type 1 diabetes mellitus.Pediatric Res,2004;55(5):830-835.
[44] Reimer MK,Pacini G,Ahren B. Dose-Dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology,2003,144(3):916-921.
[45] Carswell EA,Old LJ,Kassel RL,et al.An endotoxin—induced serum factor that cause necrosis of tumors.Proc.nat1.Acad.Sci.USA,1975,72(9):3666-3670.
[46] Lofgren P,Van Harmelen V,Reynisdottir S,et al. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue.Diabetes,2000;49(5):688-692.
[47] Nicaud V,Raoux S, Poirier O,et al.The TNF alpha/G308A polymorphism influences insulin sensitivity in offspring of patients with coronary heart disease: the European Atherosclerosis Research StudyⅡ. Atherosclerosis,2002;161(2):317-325.
[48]孟德连,林亚秋,杨公社,等.肿瘤坏死因子-α(TNF-α)与肥胖.黄牛杂志,2004;30(2):32-35.
[49] Declercq W, Vandenabeele P,Fiers W. Dimerization of chimeric erythropoietin/75kDa tumour necrosis factor (TNF) receptors transduces TNF signals:necessity for the 75 kDa-TNF receptor transmembrane domain.Cytokine,1995;7(7):701-709.
[50] Herrmann SM, Ricard S, Nicaud V, et al.Polymorphisms of the tumour necrosis factor—alpha gene,coronary heart disease and obesity.Eur J Clin Invest,1998;28(1):59-66.
[51] Katsuki A,Sumida Y, Murashima S,et al.Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab,1998;83(3):859-862.
[52] Rosmand R. Associntion studies of genetic polymorphisms in central obesity:a critical review. International Journal of Obesity,2003(27) :1141-1151.
[53] Prins JB,Niesler CU,Winterford CM,et al.Tumor necrosis factor-alpha induces apoptosis of human adipose cell. Diabetes,1997;46(12):1939—1944.
[54] Nisoli E,Carruba MO,Tonello C,et al.Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2,leptin,uncoupling proteins 2 and 3 ,and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes,2000;49(3):319—324.
[55] Doerrler W,Feingold KR,Grunfeld C.Cytokines induce catabolic effects in cultured adipocytes by multiple mechanisms.Cytokine,1994;6(5):478-484.
[56]邓正照,钱荣立.糖尿病脂代谢异常与治疗.中国糖尿病杂志,2001,9(4):251-254.
[57] Engelman JA, Berg AH,Lewis RY,et al.Tumor necrosis factor alpha-mediated insulin resistance,but not dedifferentiation,is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes.Mol Endocrinol,2000;14(10):1557-1569.
[58]王琦.9种基本中医体质类型的分类及其诊断表述依据.北京中医药大学学报,2005;28(4):1-8.
[59]董静,王琦,王东坡,等.从痰湿体质角度论析代谢综合征.北京中医药大学学报,2006;29(12):802-803.
[60]谢淑芸,霍艳明.试述代谢综合征的病因病机.中华实用中西医杂志,2007;20(13):1186-1187.
[61]卢立广,叶子.滋阴清心汤治疗代谢综合征63例观察.浙江中医杂志,2005;40(5):200.
[62]朗宁,刘贵阳.代谢综合征证治探讨.中医药学刊,2005;23(1):1289-1290.
[63]徐远.中医治疗代谢综合征的思路与方法.中医杂志,2003;44(4):301-302.
[64]刘志龙,李锡杰.浅谈代谢综合征的辨证论治.新中医,2007;39(3):88-89.
[65]王德玉.论肝与代谢综合征.浙江中西医结合杂志,2004;14(1):23-24.
[66]刘荣东,黄如萍.痰证与代谢综合征关系的探讨.中国中医基础医学杂志,2006;12(12):947-948.
[67]李东晓.痰与代谢综合征.中国中医基础医学杂志,2005;11(2):144-146.
[68]王群江,潘智敏.痰瘀因素与代谢综合征.辽宁中医药大学学报,2006;8(6):76.
[69]张雪红,宋巧凤.桃红四物汤加减治疗X综合征20例.中国中医急症,2002;11(2):137.
[70]潘善余.代谢综合征的病因病机及治疗.中医药学刊,2006;24(10):1805-1806.
[71]魏治鹏,郭宏敏.代谢综合征中的郁和瘀.辽宁中医杂志,2006;33(7):803-804
[72]李晓政,闫彩香.益肾法治疗代谢综合征痰瘀证.中国中医药信息杂志,2007;14(2):19-21.
[73]仝小林,张志远.中医对代谢综合征的认识和治疗.中医杂志,2OO2;43(9):708-709.
[74]王琦,李英帅.中医对代谢综合征的认识及辩治探讨(下).浙江中医杂志,2006;41(11):623-625.
[75]张兴军.黄连温胆汤加味治疗代谢综合征(MS)18例.中国当代医学,2006;20(5):93.
[76]陈义春,吴隆庆.益气降浊祛瘀方干预治疗代谢综合征临床观察.中国中医药信息杂志,2007;14(1):75.
[77]欧阳钢,舒琳,徐小梅,等.针刺干预治疗代谢综合征的临床研究.中国针灸学会临床分会第十五届全国针灸学术研讨会论文集,2007:78-82.
[78]翟耀,巩殿琴,陈德成,等.针刺治疗糖尿病及心血管并发症的临床研究.中国针灸,1996;8:11-13.
[79]李春娟,徐太生,冯占荣.仲景五苓散法对实验性代谢综合征大鼠高血压的影响.吉林中医药,2007;27(5):56.
[80]赵瑛,李蔚,祖莹,等.葛根素对实验性代谢综合征大鼠血脂影响的研究.中国中医药科技,2007;14(1):29-30.
[81]顾国龙,刘铮.泽泻汤治疗高血压病合并高脂血症.湖北中医杂志,2003;25(4):9-10.
[82]姜剑华,姜华新.泽泻汤加味治疗梅尼埃病68例.中华中西医学杂志,2005;3(6) :93-94.
[83]王玉仙,马学荣.泽泻汤加味治疗高脂血症103例.陕西中医,2005;26(2) :103-104.
[84]陈利群.半夏白术天麻汤合泽泻汤加味对痰湿壅盛型高血压病体重指数、降压效果的影响.中国中医急症,2007;16(6) :650-651.
[85]方校良,竹剑平.大黄壳聚糖片的减肥药效研究.浙江中西医结合杂志,2000;10(12):724-725.
[86]李媛,王保芝,岂春晓,等.一种新的肥胖大鼠模型的制备方法.河北医科大学学报,2005;26(4):305-307.
[87] Dobiasova M,Frohlich J.The plasma parameter log(TG/HDL-c)as an atherogenic index:correlation with lipoprotein particle size and esterification rate in apoB—lipoprotein—depleted plasma(FER(HDL)).Clin Bioc,2001;34(7):583-588.
[88]李光伟,潘孝仁,lilliojas,等.检测人群胰岛素敏感性的一项新指数.中华内科学杂志,1993;32(10):656-660.
[89]郭宏昌,牛晓亚,张向东,等.痰浊证与血脂水平关系的研究.河南中医药学刊,1998;13(6):18.
[90]周美芳.从痰瘀论治高脂血症88例临床观察.贵阳中医学院学报,2005;27(1):43.
[91]张永涛.论酶与NIDDM胰岛素抵抗的关系.河南中医,2001;21(6):3-5.
[92]职利琴,裴纪文,周数之.痰瘀与原发性高血压病.陕西中医,2002;23(2):140-141.
[93]张丽霞,宰军华,张钦现.二陈汤合泽泻汤对实验性高脂血症大鼠血脂的调节作用.中国实验方剂学杂志,1998;6(4):61.
[94]李晨辉,尉中民,张秋菊,等.泽泻汤加味防治高脂血症及利胆作用的实验研究.北京中医,2001;(6):46-48.
[95]唐雪梅,翟玉祥,刘涛,等.加味泽泻饮对实验性高脂血症大鼠血液流变学及血清一氧化氮的影响.中国实验方剂学杂志,2006;12(5):26-28.
[96] Aiston S,Agius L. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin.Diabetes,1999;48(1):15-20.
[97] Shek EW,Brands MW,Hall JE.Chronic leptin infusion increase arterial pressure. Hypertension,1998;31(1 Pt 2):409-414.
[98] Chua SC Jr,Chung WK, Wu-Peng XS,et al.Phenotypes of mouse diabetes and rat fatty due to mutations in the OB(1eptin)receptor.Science,1996;271(5251):994-996.
[99] Dieguez C,Casanueza FF.Ghrelin:a step forward in the understanding of somatotroph cell function and growth regulation.Eur J Endocrinol,2000;142(5):413-417.
[100] Liu X, York DA , Bray GA. Regulation of ghrelin gene expression in stomach and feeding response to a ghrelin analogue in two strains of rats. Peptides,2004;25 (12):2171-2177.
[101] Nakazato M,Murakami N ,Date Y,et al.A role for ghrelin in the central regulation of feeding.Nature,2001;409(6817):194-l98.
[102] Shintani M,Ogawa Y,Ebihara K,et al.Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes,200l;50(2):227-232.
[103]李琳,吴永华,洪天配,等.Ghrelin抑制胰岛β细胞胰岛素释放的机制探讨.中国糖尿病杂志.2006;14(6):452—454.
[104]毛微波,郭晓蕙,高妍,等.Ghrelin促进大鼠胰岛素合成及高葡萄糖诱导的胰岛素分泌.基础医学与临床,2004,24(4) :432-435.
[105] Hotamisligil GS,Shargill NS,Spiegelman BM.Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance.Science,1993;259(5091):87-91.
[106] Hotamisligil GS,Spiegelman BM.Tumor necrosis factor-alpha:a key component of the obesity-diabetes link.Diabetes,1994;43 (11):1271—1278.
[107] Uysal KT,Wiesbrock SM,Marino MW,et al.Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function.Nature,1997;389 (6651):610—614.
[108] Uysal KT,Wiesbrock SM,Hotamisligil GS.Functional analysis of tumor necrosis factor(TNF)receptors in TNF-alpha-mediated insulin resistance in genetic obesity.Endocrinology,1998;139 (12):4832—4838.
[109] Borst SE, Lee y, Conover CF, et al.Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle,but not adipose tissue.Am J Physiol Endocrinol Metab,2004;287(5):934-938.
[110] Moller DE.Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.Trends Endocrinol Metab,2000;11(6):212—217.
[111] Tagami S, Inokuchi Ji J, Kabayama K, et al.Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem,2002;277(5) :3085-3092.
[112] Lofgren P, van Harmelen V ,Reynisdottir S,et al.Secretion of tumor necrosid factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue.Diabetes,2000;49(5):688-692.
[113]邹大进.蛋白酪氨酸磷酸酶1B的普遍激活:胰岛素抵抗和瘦素抵抗可能的共同发病机制.国际内分泌代谢杂志,2007;27(5) :293-295.
[114]王重建,杨年红,许明佳,等.肥胖和肥胖抵抗大鼠神经肽Y及其受体基因表达的研究.营养学报,2006;28(2) :116-119.
[115] Milewicz A,Mikulski E,Bidzinska B. Plasma insulin, cholecystokinin,galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus. Int J Obes Relat Metab Disord,2000;24 suool 2:152-153.
[116] Myrsen-Axcrona U,Karlsson S,Sundler F , et al. Dexamethasone induces neuropeptide Y(NPY) expression and impairs insulin release in the insulin- producing cell line RINm5F.Release of NPY and insulin through different pathways. Journ Biol Chem,1997;272(16):1079O-10796.
[117] Wang ZL,Bennet WM,Wang RM,et al. Evidence of a paracrine role of neuronpeptide-Y in the regulation of insulin release from pancreaticislets of normal and dexamethasone-treated rats. Endocrinology,1994;135(1):200-206.
[118]梁凤霞,陈瑞,王华,等.针刺对糖尿病大鼠血浆神经肽Y的影响.中国针灸,2004;24(12):860-862.
[119] Adeghate E,Ponery AS,Pallot DJ,et al. Distribution of vasoactive intestinal polypeptide,neuropeptide-Y and substance P and their effects on insulin secretion from the in vitro pancreas of normal and diabetic rats.PePtides,2001;22(1):99-107.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |